ZYLOXTB (02190) Issues Profit Alert, Anticipates Annual Net Profit Attributable to Shareholders to Exceed RMB 240 Million, Up Approximately 139.4% YoY

Stock News01-29

ZYLOXTB (02190) announced that for the fiscal year ending December 31, 2025 (the reporting period), the net profit attributable to the company's equity holders is expected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% compared to RMB 100.3 million for the year ended December 31, 2024. Furthermore, the Group's revenue for the reporting period is anticipated to surpass RMB 1.05 billion, marking an approximate 34.6% increase from the RMB 780 million recorded in the prior year. This significant improvement in performance is primarily driven by three key factors: 1) continued robust growth in domestic sales of several flagship products, including the Qilin Blood Flow Diverter, neurovascular guidewires, the UltraFree Drug-Eluting PTA Balloon Dilatation Catheter (UltraFree DCB), and the Swan Venous Radiofrequency Ablation Catheter; 2) international sales more than doubling year-on-year due to successful market expansion into multiple regions; and 3) a relatively stable gross profit margin, coupled with continuously improving operational efficiency.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1115845439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-29 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115845439","market":"fut","top_or_hot":-1,"title":"ZYLOXTB (02190) Issues Profit Alert, Anticipates Annual Net Profit Attributable to Shareholders to Exceed RMB 240 Million, Up Approximately 139.4% YoY","media":"Stock News","content":"<p>ZYLOXTB (02190) announced that for the fiscal year ending December 31, 2025 (the reporting period), the net profit attributable to the company's equity holders is expected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% compared to RMB 100.3 million for the year ended December 31, 2024.\nFurthermore, the Group's revenue for the reporting period is anticipated to surpass RMB 1.05 billion, marking an approximate 34.6% increase from the RMB 780 million recorded in the prior year.\nThis significant improvement in performance is primarily driven by three key factors: 1) continued robust growth in domestic sales of several flagship products, including the Qilin Blood Flow Diverter, neurovascular guidewires, the UltraFree Drug-Eluting PTA Balloon Dilatation Catheter (UltraFree DCB), and the Swan Venous Radiofrequency Ablation Catheter; 2) international sales more than doubling year-on-year due to successful market expansion into multiple regions; and 3) a relatively stable gross profit margin, coupled with continuously improving operational efficiency.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ZYLOXTB (02190) Issues Profit Alert, Anticipates Annual Net Profit Attributable to Shareholders to Exceed RMB 240 Million, Up Approximately 139.4% YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZYLOXTB (02190) Issues Profit Alert, Anticipates Annual Net Profit Attributable to Shareholders to Exceed RMB 240 Million, Up Approximately 139.4% YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-29 21:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>ZYLOXTB (02190) announced that for the fiscal year ending December 31, 2025 (the reporting period), the net profit attributable to the company's equity holders is expected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% compared to RMB 100.3 million for the year ended December 31, 2024.\nFurthermore, the Group's revenue for the reporting period is anticipated to surpass RMB 1.05 billion, marking an approximate 34.6% increase from the RMB 780 million recorded in the prior year.\nThis significant improvement in performance is primarily driven by three key factors: 1) continued robust growth in domestic sales of several flagship products, including the Qilin Blood Flow Diverter, neurovascular guidewires, the UltraFree Drug-Eluting PTA Balloon Dilatation Catheter (UltraFree DCB), and the Swan Venous Radiofrequency Ablation Catheter; 2) international sales more than doubling year-on-year due to successful market expansion into multiple regions; and 3) a relatively stable gross profit margin, coupled with continuously improving operational efficiency.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1100","symbol_name":"医疗保健设备","start_time":0,"source_url":"","article_id":"1115845439","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115845439","pubTimestamp":1769691736,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"ZYLOXTB (02190) announced that for the fiscal year ending December 31, 2025 (the reporting period), the net profit attributable to the company's equity holders is expected to exceed RMB 240 million,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1100":"医疗保健设备","BK1587":"次新股","BK1574":"生物医药B类股","BK1583":"高瓴概念","02190":"归创通桥"},"translate_title":"ZYLOXTB(02190)发盈警，预计全年股东应占纯利超2.4亿元同比增约139.4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02190":1},"content_text":"ZYLOXTB (02190) announced that for the fiscal year ending December 31, 2025 (the reporting period), the net profit attributable to the company's equity holders is expected to exceed RMB 240 million, representing a year-on-year increase of approximately 139.4% compared to RMB 100.3 million for the year ended December 31, 2024.\nFurthermore, the Group's revenue for the reporting period is anticipated to surpass RMB 1.05 billion, marking an approximate 34.6% increase from the RMB 780 million recorded in the prior year.\nThis significant improvement in performance is primarily driven by three key factors: 1) continued robust growth in domestic sales of several flagship products, including the Qilin Blood Flow Diverter, neurovascular guidewires, the UltraFree Drug-Eluting PTA Balloon Dilatation Catheter (UltraFree DCB), and the Swan Venous Radiofrequency Ablation Catheter; 2) international sales more than doubling year-on-year due to successful market expansion into multiple regions; and 3) a relatively stable gross profit margin, coupled with continuously improving operational efficiency.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1115845439","isCrawlerRequest":true}